Clinical Research Directory

Inclusion Criteria: * First recurrence of platinum-sensitive, invasive epithelial ovarian, fallopian tube, or primary peritoneal cancer, regardless of initial stage. * A progression-free interval of at least 6 months after the end of the last platinum-containing regimen. * Demonstrated response during neoadjuvant chemotherapy after recurrence (Complete Response/Partial Response/Stable Disease according to RECIST 1.1 or GCIG CA-125 response, which is a ≥50% reduction in pre-treatment CA-125 level sustained for ≥28 days). * Women aged 19 years or older. * The tumor is judged to be completely resectable by surgery (R0) based on the judgment of an experienced surgeon * Patients who provide signed and written informed consent and consent to data transfer and processing. Exclusion Criteria: * Patients without recurrence * Patients with non-epithelial tumors or borderline tumors. * Patients with second, third, or subsequent recurrence. * Patients with a secondary malignancy treated with laparotomy and other neoplasms, where the treatment is expected to interfere with the treatment of recurrent ovarian cancer or significantly affect prognosis. * Patients with platinum-refractory tumors (i.e., progression during chemotherapy or recurrence within 6 months after the end of the previous first platinum-containing regimen). * Cases where only palliative surgery is planned. * Radiological signs suggestive of metastasis that are considered completely unresectable. * Any comorbidity that precludes surgery and/or chemotherapy (e.g., poor general condition, severe infection, conditions that may cause severe bleeding, severe renal disease, etc.). * Any medical history that may cause excessive surgical risk pre- or post-operatively. * Medications being taken that pose a significant surgical risk (e.g., oral anticoagulants, bleeding risk due to bevacizumab). * Absence of evaluable archived tumor tissue.